tiprankstipranks
Trending News
More News >
Entrada Therapeutics Reports Strong 2024 Financial Results
PremiumCompany AnnouncementsEntrada Therapeutics Reports Strong 2024 Financial Results
2M ago
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating
Premium
Ratings
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating
2M ago
Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year
Premium
The Fly
Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year
2M ago
Entrada announces FDA removal of clinical hold on ENTR-601-44
PremiumThe FlyEntrada announces FDA removal of clinical hold on ENTR-601-44
2M ago
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks
Premium
Ratings
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks
2M ago
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial
Premium
Company Announcements
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial
2M ago
Entrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright
PremiumThe FlyEntrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright
5M ago
Entrada Therapeutics’ Q3 2024 Financial Highlights
Premium
Company Announcements
Entrada Therapeutics’ Q3 2024 Financial Highlights
5M ago
Entrada Therapeutics reports Q3 EPS (35c), consensus (73c)
Premium
The Fly
Entrada Therapeutics reports Q3 EPS (35c), consensus (73c)
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100